Catalan company INBRAIN Neuroelectronics, a member of Catalonia.health, has announced the completion of patient enrolment in its first-in-human study of graphene-based neural interfaces for brain decoding and mapping.

Catalan biotech company Aniling, a member of Catalonia.health, has announced a strategic collaboration with Illumina to advance unified genomic and epigenetic assays in oncology.

Catalan biotech company Sequentia Biotech, a member of Catalonia.health, has announced the achievement of CE-IVD marking under the new European IVDR regulation for its MICK Clinical™ solution, designed for gastrointestinal pathogen diagnostics.

Kymos Group, a European contract research organization specialized in services for the biopharmaceutical industry and a Catalonia.health’s member, has announced the acquisition of Particle Analytical ApS, a Danish company specialized in particle analysis and solid-state characterization.

Croda International Plc, a global leader in specialty ingredients and a Catalonia.health member company, has announced a strategic supply partnership with Amino GmbH, a leading manufacturer of pharmaceutical-grade amino acids, aimed at strengthening the global availability of high purity amino acids for pharmaceutical formulation and biomanufacturing.

Ysios Capital, a European venture capital firm specialized in life sciences and a Catalonia.health member company, has announced the launch of InceptionBio, a new fund with a target size of €100 million focused on biotech company creation and early-stage project development.

Catalonia.health is part of the AYRA project consortium, an industrial research initiative in digital health that is now entering its second phase with new clinical, technological and public health objectives.

The association participates in two meetings to consolidate strategic alliances within the Spanish and Catalan ecosystems.

This week featured two strategic meetings that strengthen the collaborative fabric of Spain's and Catalonia's biohealth sector.

Peptomyc has announced the closing of a €5 million financing round to support the next stage of development of OMO-103, its therapeutic candidate based on direct MYC inhibition. The financing strengthens the company’s clinical and industrial activity and supports continued progress in oncology.

Catalonia.health facilitates a direct dialogue between member CEOs and the Director General of AEI to explore ways to improve the relationship between the private sector and Spain's research administration.